Technology
Health
Biotechnology

Aimmune Therapeutics

$20.10
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.10 (-0.50%) Today
-$0.10 (-0.50%) Today

Why Robinhood?

You can buy or sell AIMT and other stocks, options, ETFs, and crypto commission-free!

About

Aimmune Therapeutics, Inc. Common Stock, also called Aimmune Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Read More Its portfolio includes the characterized oral desensitization immunotherapy system. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.

Employees
215
Headquarters
Brisbane, California
Founded
2011
Market Cap
1.26B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
559.40K
High Today
$20.47
Low Today
$20.06
Open Price
$20.39
Volume
59.41K
52 Week High
$36.12
52 Week Low
$19.25

Collections

Technology
Health
Biotechnology
Therapy
Medical
Biopharmaceutical
Research And Development
Food

News

Yahoo FinanceJun 2

Pivotal Phase 3 ARTEMIS Trial Data Demonstrates Consistent Safety and Efficacy of AR101 in Children and Adolescents with Peanut Allergy

358

Earnings

-$0.97
-$0.86
-$0.74
-$0.63
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 8, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.